Gadavist Dosing Complexities To Be Handled With Packaging, Not REMS
This article was originally published in The Pink Sheet Daily
Executive Summary
Bayer's newly approved gadolinium-based contrast agent only needs half the dose of other such products. The label eschews comparative safety claims.